Despite strong growth, the infusion business is still in the early stages of expanding its chronic specialty portfolio. Q: Can you discuss the growth initiatives, particularly in infusion, and the focus on expanding the chronic portfolio? A: Jon Rousseau, CEO: We saw broad-based growth across the organization, with significant volume growth in both provider and […]
Despite strong growth, the infusion business is still in the early stages of expanding its chronic specialty portfolio.
Q: Can you discuss the growth initiatives, particularly in infusion, and the focus on expanding the chronic portfolio? A: Jon Rousseau, CEO: We saw broad-based growth across the organization, with significant volume growth in both provider and pharmacy segments. In infusion, we experienced double-digit growth in both acute and chronic specialty areas. We launched a concierge program for IVIG and are building out similar programs for targeted therapies, which contributed to this growth.
Q: With your current leverage position, are you considering larger M&A opportunities, and what leverage level would you be comfortable with for the right asset? A: Jon Rousseau, CEO: We are pleased with our balance sheet and aim to maintain leverage in the mid-2s. While we have flexibility for larger transactions, our focus remains on disciplined, strategic acquisitions, primarily geographical expansions and tuck-ins that align with our long-term goals.
Q: How is the overall Medicare environment impacting your business, and what are your thoughts on value-based care arrangements? A: Jon Rousseau, CEO: The Medicare environment has been consistent, with no major changes affecting us. We are actively pursuing value-based care opportunities, including applying for the new lead ACO program. Our focus is on scaling our operations to serve patients across various settings with high-quality outcomes.
Q: Can you provide an update on the revenue headwinds from IRA, specialty infusion, and brand to generic conversions? A: Jennifer Phipps, CFO: We are tracking towards our expected numbers, with a total revenue impact of approximately $606 million for 2026. This includes $175 million from IRA in Home & Community, $181 million in specialty and infusion, and $250 million from brand to generic conversions.
Q: What are the key drivers behind the gross profit per script increase, and is there room for further improvement? A: Jon Rousseau, CEO: The increase was driven by growth in specialty and infusion, brand to generic mix shifts, purchasing efficiencies, and fee-for-service agreements. While we don’t expect significant further gains, maintaining stability in gross profit per script is our goal.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.…Read more by GuruFocus News